Selumetinib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 10mg, 25mg
Reference Brands: Koselugo (USA)
Category:
Neurology
Selumetinib is a selective inhibitor of the enzymes MEK1 and MEK2, which are part of a signalling pathway involved in cell growth and division. By blocking MEK1/2, selumetinib helps reduce abnormal growth of nerve-sheath tumors (plexiform neurofibromas) in people with genetic disorder Neurofibromatosis type 1 (NF1). Koselugo is indicated for patients (children and now adults) with symptomatic, inoperable plexiform neurofibromas — helping shrink tumor volume or slow growth when surgical removal is not feasible.
Selumetinib is available in Capsules
and strengths such as 10mg, 25mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Selumetinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Selumetinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing